| Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations J Gong, A Chehrazi-Raffle, S Reddi, R Salgia Journal for immunotherapy of cancer 6 (1), 8, 2018 | 1353 | 2018 |
| Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial N Dizman, L Meza, P Bergerot, M Alcantara, T Dorff, Y Lyou, P Frankel, ... Nature medicine 28 (4), 704-712, 2022 | 335 | 2022 |
| The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies J Gong, A Chehrazi‐Raffle, V Placencio‐Hickok, M Guan, A Hendifar, ... Clinical and translational medicine 8 (1), e9, 2019 | 93 | 2019 |
| Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma A Chehrazi-Raffle, L Meza, M Alcantara, N Dizman, P Bergerot, N Salgia, ... Journal for Immunotherapy of Cancer 9 (3), e002009, 2021 | 34 | 2021 |
| Wnt/β-catenin signaling and immunotherapy resistance: lessons for the treatment of urothelial carcinoma A Chehrazi-Raffle, TB Dorff, SK Pal, Y Lyou Cancers 13 (4), 889, 2021 | 34 | 2021 |
| Toxoplasma gondii serology and outcomes after heart transplantation: contention in the literature A Chehrazi-Raffle, M Luu, Z Yu, F Liou, M Kittleson, M Hamilton, ... Transplantation proceedings 47 (6), 1949-1953, 2015 | 28 | 2015 |
| Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma ZB Zengin, A Chehrazi-Raffle, NJ Salgia, R Muddasani, S Ali, L Meza, ... Urologic Oncology: Seminars and Original Investigations 40 (2), 25-36, 2022 | 22 | 2022 |
| Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial H Ebrahimi, N Dizman, L Meza, J Malhotra, X Li, T Dorff, P Frankel, ... Nature Medicine 30 (9), 2576-2585, 2024 | 21 | 2024 |
| Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial. H Ebrahimi, LA Meza, K Lee, J Malhotra, M Alcantara, ZB Zengin, ... Journal of Clinical Oncology 41 (17_suppl), LBA104-LBA104, 2023 | 16 | 2023 |
| Complementary role of circulating tumor DNA assessment and tissue genomic profiling in metastatic renal cell carcinoma ZB Zengin, C Weipert, NJ Salgia, N Dizman, J Hsu, L Meza, ... Clinical Cancer Research 27 (17), 4807-4813, 2021 | 15 | 2021 |
| Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study TK Choueiri, L Albiges, P Barthélémy, R Iacovelli, S Emambux, ... The Lancet 404 (10460), 1309-1320, 2024 | 14 | 2024 |
| Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma N Dizman, A Govindarajan, ZB Zengin, L Meza, N Tripathi, N Sayegh, ... Clinical Genitourinary Cancer 21 (5), 530-536, 2023 | 12 | 2023 |
| First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma. LA Meza, N Dizman, PG Bergerot, TB Dorff, Y Lyou, PH Frankel, V Mira, ... Journal of Clinical Oncology 39 (15_suppl), 4513-4513, 2021 | 12 | 2021 |
| Ultrasensitive circulating tumor DNA pilot study distinguishes complete response and partial response with immunotherapy in patients with metastatic renal cell carcinoma A Chehrazi-Raffle, R Muddasani, N Dizman, JA Hsu, L Meza, ZB Zengin, ... JCO precision oncology 7, e2200543, 2023 | 11 | 2023 |
| Unique Spectrum of Activating BRAF Alterations in Prostate Cancer A Chehrazi-Raffle, H Tukachinsky, E Toye, S Sivakumar, AB Schrock, ... Clinical Cancer Research 29 (19), 3948-3957, 2023 | 10 | 2023 |
| An update on the treatment of papillary renal cell carcinoma NS Chawla, N Sayegh, S Prajapati, E Chan, SK Pal, A Chehrazi-Raffle Cancers 15 (3), 565, 2023 | 10 | 2023 |
| Genomic and clinical prognostic factors in patients with advanced urothelial carcinoma receiving immune checkpoint inhibitors NS Chawla, N Sayegh, N Tripathi, A Govindarajan, ZB Zengin, EJ Phillip, ... Clinical Genitourinary Cancer 21 (1), 69-75, 2023 | 8 | 2023 |
| Renal cell carcinoma with urinary bladder metastasis: a case report with metachronous genomic analyses A Chehrazi-Raffle, J Malhotra, S Salgia, C Favorito, JA Hsu, H Wu, SK Pal JCO Precision Oncology 5, PO. 20.00423, 2021 | 8 | 2021 |
| Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy MB Alcantara, WS Tang, D Wang, D Kaniowski, E Kang, N Dizman, ... Frontiers in Immunology 14, 1274781, 2024 | 7 | 2024 |
| Barriers to clinical trial implementation among Community care centers H Ebrahimi, S Megally, E Plotkin, L Shivakumar, NJ Salgia, ZB Zengin, ... JAMA Network Open 7 (4), e248739-e248739, 2024 | 4 | 2024 |
